MK2140-006
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies
Description: This trial assesses the effectiveness of MK2140 used on its own or in combination with other treatments in patients with aggressive and Indolent B-cell malignancies
Study Phase: Phase 2
Principal Investigator: Dr Carmel Waldron
Further information
